Cardiovascular Therapeutic Drugs Market
Cardiovascular Therapeutic Drugs Market Size, Share & Industry Analysis, By Drug Class (Antihypertensive Agents, Antihyperlipidemic Agents, Anticoagulants, Antiplatelet Drugs, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Route of Administration (Oral, Parenteral, Others), By Indication (Hypertension, Hyperlipidemia, Coronary Artery Disease, Arrhythmia, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) - Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview:
The global Cardiovascular Therapeutic Drugs Market is projected to grow at a CAGR of 3.8% from 2024 to 2031. The market value is expected to increase from XX USD in 2024 to YY USD by 2031. North America currently dominates the market, followed closely by Europe and Asia-Pacific. Key metrics include the increasing prevalence of cardiovascular diseases, growing geriatric population, and rising adoption of novel therapeutic agents.
The cardiovascular therapeutic medicines industry is steadily growing as the global incidence of heart disease rises. According to the World Health Organisation (WHO), cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, killing an estimated 17.9 million people each year. This high frequency, combined with advances in drug development and rising healthcare costs, is propelling market growth.
Market Dynamics:
Market Trend: Increasing adoption of combination therapies for improved efficacy and patient compliance
The cardiovascular therapeutic medicines market is experiencing a considerable shift towards the use of combination therapy. This technique entails combining various medications with distinct modes of action in a single formulation to improve therapeutic outcomes. Combination medications are very effective for controlling complex cardiovascular disorders like hypertension and dyslipidaemia. For example, the combination of an ACE inhibitor and a calcium channel blocker has demonstrated more success in blood pressure control than monotherapies. This trend is motivated by the need to improve patient compliance, minimise pill burden, and increase treatment efficacy. Pharmaceutical companies are putting more emphasis on creating fixed-dose combination medications, which are projected to fuel market growth in the future years.
Market Driver: Rising prevalence of cardiovascular diseases and associated risk factors
The rising frequency of cardiovascular diseases and risk factors is a major driver of the cardiovascular therapeutic medicines market. According to the American Heart Association's 2021 Heart Disease and Stroke Statistics update, roughly half of all individuals in the United States suffer from cardiovascular disease. Obesity, diabetes, and hypertension are becoming increasingly common around the world. For example, the International Diabetes Federation predicts that the number of adults with diabetes would rise from 463 million in 2019 to 700 million by 2045. This growing illness load is driving a significant demand for cardiovascular therapeutic medications. Governments and healthcare organisations around the world are undertaking awareness campaigns and preventive measures, strengthening the market for cardiovascular drugs.
Market Restraint: Patent expirations and increasing penetration of generic drugs
The cardiovascular therapeutic pharmaceuticals market is facing a severe threat in the form of patent expirations and the resulting flood of generic alternatives. As patents for blockbuster cardiovascular medications expire, generic alternatives enter the market, causing price erosion and lower market share for branded products. For example, the patent expiration of Lipitor, the world's best-selling medicine, resulted in a huge decline in sales for the maker. According to the Food and Drug Administration (FDA), generic medications make up around 90% of all prescription drug purchases in the United States. This tendency is especially noticeable in the cardiovascular area, where many established medications have lost their patent protection. The growing availability of low-cost generic alternatives puts pressure on branded medication producers' profit margins and may limit investment in research and development of new cardiovascular medicines.
Segment Overview:
Antihypertensive agents dominate the market due to the high prevalence of hypertension globally.
Antihypertensive medications continue to dominate the cardiovascular therapeutic drug market, accounting for the lion's share. This dominance is primarily due to the high prevalence of hypertension worldwide and the crucial role these medications play in preventing cardiovascular problems.
Recent advances in antihypertensive medication have focused on increasing efficacy while minimising negative effects. For example, a study published in the New England Journal of Medicine described a new class of antihypertensive medications known as dual angiotensin receptor-neprilysin inhibitors (ARNIs), which have demonstrated better outcomes in heart failure patients than traditional therapy. This advancement indicates continued efforts to improve the efficacy of antihypertensive therapies.
Antihypertensive medications are also preferred because they are more cost-effective in healthcare systems. According to a detailed research conducted by the American Heart Association, proactive hypertension therapy might save 56,000 cardiovascular events and 13,000 fatalities in the United States each year, saving significant healthcare costs. Antihypertensive medications continue to dominate the cardiovascular therapeutic drug industry due to their economic benefits as well as the clinical necessity of blood pressure control.
Regional Outlook:
North America leads the cardiovascular therapeutic drugs market, driven by high disease prevalence and advanced healthcare infrastructure.
North America now dominates the worldwide cardiovascular therapeutic medicines market, with the United States playing the leading role. The region's leadership is due to a high prevalence of cardiovascular disorders, modern healthcare infrastructure, and large investments in research and development of novel cardiovascular medicines.
Recent news from the region emphasises continued efforts to enhance cardiovascular care. The American Heart Association has modified its primary preventive guidelines for cardiovascular disease, emphasising the importance of lifestyle changes in addition to pharmacological therapies. This comprehensive approach is projected to increase demand for both traditional and novel cardiovascular medications in the region.
Key figures highlight the value of cardiovascular therapeutic medications in North America. According to the Centres for Disease Control and Prevention (CDC), heart disease is the top cause of mortality in the United States, responsible for around 655,000 fatalities each year. The prevalence of high blood pressure in persons aged 18 and up is 45.4%, indicating a considerable market opportunity for antihypertensive medications.
The Heart and Stroke Foundation of Canada states that nine out of 10 Canadians have at least one risk factor for heart disease or stroke. This high risk profile has resulted in increasing government attempts to improve cardiovascular health, such as improved access to treatment medications. The Canadian Agency for Drugs and Technologies in Health has been aggressively reviewing novel cardiovascular drugs and proposing their inclusion in public drug plans, which is projected to increase market growth in the country.
Competitive Intelligence:
The cardiovascular therapeutic medicines market is characterised by the presence of multiple prominent companies, each attempting to preserve and extend their market share using a variety of techniques. Pfizer Inc., Novartis AG, Merck & Co., Inc., and AstraZeneca plc are among the industry's top players.
Pfizer Inc., a multinational pharmaceutical company, has maintained its dominant position in the cardiovascular medications market with a diversified portfolio and ongoing innovation. The company's cardiovascular franchise, which includes medications like as Eliquis (apixaban), has contributed significantly to its revenue growth. In its most recent financial report, Pfizer announced a 10% year-over-year growth in Eliquis sales, reflecting the drug's robust market performance.
Novartis AG has been focussing on increasing its footprint in the heart failure market. Entresto (sacubitril/valsartan) has had rapid growth, with revenues increasing by 44% in the most recent fiscal year. Novartis is also investing extensively in R&D, with several promising cardiovascular medications in the pipeline.
AstraZeneca plc has strengthened its position in the cardiovascular industry by making smart acquisitions and forming collaborations. The recent acquisition of Alexion Pharmaceuticals is intended to strengthen the company's cardiovascular and metabolic disease portfolio. Brilinta (ticagrelor), AstraZeneca's medication, remains a key growth driver in the cardiovascular market.
While exact data are closely guarded, industry analysts believe that the top five players control roughly 40-45% of the worldwide cardiovascular therapeutic medicines market. The remaining market share is split between smaller regional firms and new biotechnology companies that concentrate on novel drug development.
Looking ahead, the competitive landscape is projected to change with the arrival of new companies and the development of novel therapies. The emphasis on personalised medicine and tailored medicines is expected to influence market dynamics in the future years, as companies invest in biomarker research and precision medicine techniques for cardiovascular illnesses.
Analyst Opinion:
The cardiovascular therapeutic medicines industry is expected to undergo considerable transformation in the future years. The growing emphasis on personalised medicine in cardiovascular care is an important trend to keep an eye on. Advances in genetics and biomarker research are paving the path for more focused treatments, which may improve treatment outcomes while decreasing adverse effects. This shift towards precision medicine has the potential to change the market landscape in favour of companies investing in biomarker development and companion diagnostics.
Another notable trend is the increased emphasis on digital health solutions in cardiovascular disease management. The combination of medicinal medications with digital technology, such as wearable devices and smartphone apps for medication adherence and monitoring, is expected to gain traction. This development may provide new opportunity for pharmaceutical companies to differentiate their medications and enhance patient outcomes through holistic illness management solutions.
Major Players:
-
Pfizer Inc.
-
Novartis AG
-
Merck & Co., Inc.
-
AstraZeneca plc
-
Bristol-Myers Squibb Company
-
Bayer AG
-
Sanofi S.A.
-
Johnson & Johnson
-
Amgen Inc.
-
Eli Lilly and Company
Key Developments:
-
July 2023: The FDA approves a new PCSK9 inhibitor for the treatment of hypercholesterolaemia.
-
March 2024: The introduction of a first-in-class oral medication for the treatment of heart failure with intact ejection fraction.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies list by Country) (Premium)
5. COMPANY PROFILES
5.1. Pfizer Inc.
5.2. Novartis AG
5.3. Merck & Co., Inc.
5.4. AstraZeneca plc
5.5. Bristol-Myers Squibb Company
5.6. Bayer AG
5.7. Sanofi S.A.
5.8. Johnson & Johnson
5.9. Amgen Inc.
5.10. Eli Lilly and Company (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Increasing adoption of combination therapies for improved efficacy and patient compliance
6.1.2. Growing focus on personalized medicine in cardiovascular care
6.1.3. Integration of digital health solutions in cardiovascular disease management
6.2. Market Drivers
6.2.1. Rising prevalence of cardiovascular diseases and associated risk factors
6.2.2. Advancements in drug development and targeted therapies
6.2.3. Increasing healthcare expenditure and awareness about cardiovascular health
6.3. Market Restraints
6.3.1. Patent expirations and increasing penetration of generic drugs
6.3.2. Stringent regulatory requirements and high cost of drug development
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY DRUG CLASS (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Antihypertensive Agents
7.2. Antihyperlipidemic Agents
7.3. Anticoagulants
7.4. Antiplatelet Drugs
7.5. Others
8. BY DISTRIBUTION CHANNEL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Hospital Pharmacies
8.2. Retail Pharmacies
8.3. Online Pharmacies
9. BY ROUTE OF ADMINISTRATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Oral
9.2. Parenteral
9.3. Others
10. BY INDICATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. Hypertension
10.2. Hyperlipidemia
10.3. Coronary Artery Disease
10.4. Arrhythmia
10.5. Others
11. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
11.1. North America
11.1.1. United States
11.1.2. Canada
11.1.3. Mexico
11.2. South America
11.2.1. Brazil
11.2.2. Argentina
11.2.3. Rest of South America
11.3. Europe
11.3.1. Germany
11.3.2. United Kingdom
11.3.3. France
11.3.4. Italy
11.3.5. Spain
11.3.6. Russia
11.3.7. Rest of Europe
11.4. Asia-Pacific
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia
11.4.5. South Korea
11.4.6. Rest of Asia-Pacific
11.5. Middle-East
11.5.1. UAE
11.5.2. Saudi Arabia
11.5.3. Turkey
11.5.4. Rest of Middle East
11.6. Africa
11.6.1. South Africa
11.6.2. Egypt
11.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
Market Segmentation:
By Drug Class:
-
Antihypertensive Agents
-
Antihyperlipidemic Agents
-
Anticoagulants
-
Antiplatelet Drugs
-
Others
By Distribution Channel:
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
By Route of Administration:
-
Oral
-
Parenteral
-
Others
By Indication:
-
Hypertension
-
Hyperlipidemia
-
Coronary Artery Disease
-
Arrhythmia
-
Others
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511